Hanta Virus Market

ID: MRFR/Pharma/35378-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026
Hanta Virus Market Research Report By Transmission Mode (Inhalation, Contact with contaminated surfaces, Bite from infected rodents), By Diagnosis Type (Serological Tests, Molecular Tests, Antigen Tests), By Treatment Type (Supportive Care, Antiviral Therapy, Vaccination), By End User (Hospitals, Diagnostic Laboratories, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Hanta Virus Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)7.32%
2024 Market Size$ 86.53 Million
2025 Market Size$ 92.86 Million
2035 Market Size$ 188.21 Million

Key Players

Centers for Disease Control and Prevention
National Institutes of Health
World Health Organization
Public Health Agency of Canada
European Centre for Disease Prevention and Control
U.S. Department of Agriculture
Opportunities
  • Government Initiatives and Funding
  • Rising Incidence of Hanta Virus Cases
  • Growing Awareness of Zoonotic Diseases
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Transmission Mode (USD Million)
      1. 4.1.1 Inhalation
      2. 4.1.2 Contact with contaminated surfaces
      3. 4.1.3 Bite from infected rodents
    2. 4.2 Healthcare, BY Diagnosis Type (USD Million)
      1. 4.2.1 Serological Tests
      2. 4.2.2 Molecular Tests
      3. 4.2.3 Antigen Tests
    3. 4.3 Healthcare, BY Treatment Type (USD Million)
      1. 4.3.1 Supportive Care
      2. 4.3.2 Antiviral Therapy
      3. 4.3.3 Vaccination
    4. 4.4 Healthcare, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Diagnostic Laboratories
      3. 4.4.3 Research Institutes
    5. 4.5 Healthcare, BY Region (USD Million)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Centers for Disease Control and Prevention (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 National Institutes of Health (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 World Health Organization (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Public Health Agency of Canada (CA)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 European Centre for Disease Prevention and Control (EU)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 National Institute of Allergy and Infectious Diseases (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 U.S. Department of Agriculture (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 National Wildlife Health Center (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY TRANSMISSION MODE
    4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS TYPE
    5. 6.5 US MARKET ANALYSIS BY TREATMENT TYPE
    6. 6.6 US MARKET ANALYSIS BY END USER
    7. 6.7 CANADA MARKET ANALYSIS BY TRANSMISSION MODE
    8. 6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS TYPE
    9. 6.9 CANADA MARKET ANALYSIS BY TREATMENT TYPE
    10. 6.10 CANADA MARKET ANALYSIS BY END USER
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY TRANSMISSION MODE
    13. 6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS TYPE
    14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
    15. 6.15 GERMANY MARKET ANALYSIS BY END USER
    16. 6.16 UK MARKET ANALYSIS BY TRANSMISSION MODE
    17. 6.17 UK MARKET ANALYSIS BY DIAGNOSIS TYPE
    18. 6.18 UK MARKET ANALYSIS BY TREATMENT TYPE
    19. 6.19 UK MARKET ANALYSIS BY END USER
    20. 6.20 FRANCE MARKET ANALYSIS BY TRANSMISSION MODE
    21. 6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS TYPE
    22. 6.22 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
    23. 6.23 FRANCE MARKET ANALYSIS BY END USER
    24. 6.24 RUSSIA MARKET ANALYSIS BY TRANSMISSION MODE
    25. 6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS TYPE
    26. 6.26 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
    27. 6.27 RUSSIA MARKET ANALYSIS BY END USER
    28. 6.28 ITALY MARKET ANALYSIS BY TRANSMISSION MODE
    29. 6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS TYPE
    30. 6.30 ITALY MARKET ANALYSIS BY TREATMENT TYPE
    31. 6.31 ITALY MARKET ANALYSIS BY END USER
    32. 6.32 SPAIN MARKET ANALYSIS BY TRANSMISSION MODE
    33. 6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS TYPE
    34. 6.34 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
    35. 6.35 SPAIN MARKET ANALYSIS BY END USER
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY TRANSMISSION MODE
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS TYPE
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY TRANSMISSION MODE
    42. 6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS TYPE
    43. 6.43 CHINA MARKET ANALYSIS BY TREATMENT TYPE
    44. 6.44 CHINA MARKET ANALYSIS BY END USER
    45. 6.45 INDIA MARKET ANALYSIS BY TRANSMISSION MODE
    46. 6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS TYPE
    47. 6.47 INDIA MARKET ANALYSIS BY TREATMENT TYPE
    48. 6.48 INDIA MARKET ANALYSIS BY END USER
    49. 6.49 JAPAN MARKET ANALYSIS BY TRANSMISSION MODE
    50. 6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS TYPE
    51. 6.51 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
    52. 6.52 JAPAN MARKET ANALYSIS BY END USER
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY TRANSMISSION MODE
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS TYPE
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
    57. 6.57 MALAYSIA MARKET ANALYSIS BY TRANSMISSION MODE
    58. 6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS TYPE
    59. 6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
    60. 6.60 MALAYSIA MARKET ANALYSIS BY END USER
    61. 6.61 THAILAND MARKET ANALYSIS BY TRANSMISSION MODE
    62. 6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS TYPE
    63. 6.63 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
    64. 6.64 THAILAND MARKET ANALYSIS BY END USER
    65. 6.65 INDONESIA MARKET ANALYSIS BY TRANSMISSION MODE
    66. 6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS TYPE
    67. 6.67 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
    68. 6.68 INDONESIA MARKET ANALYSIS BY END USER
    69. 6.69 REST OF APAC MARKET ANALYSIS BY TRANSMISSION MODE
    70. 6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS TYPE
    71. 6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
    72. 6.72 REST OF APAC MARKET ANALYSIS BY END USER
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY TRANSMISSION MODE
    75. 6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS TYPE
    76. 6.76 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
    77. 6.77 BRAZIL MARKET ANALYSIS BY END USER
    78. 6.78 MEXICO MARKET ANALYSIS BY TRANSMISSION MODE
    79. 6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS TYPE
    80. 6.80 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
    81. 6.81 MEXICO MARKET ANALYSIS BY END USER
    82. 6.82 ARGENTINA MARKET ANALYSIS BY TRANSMISSION MODE
    83. 6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS TYPE
    84. 6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
    85. 6.85 ARGENTINA MARKET ANALYSIS BY END USER
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TRANSMISSION MODE
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS TYPE
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TRANSMISSION MODE
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS TYPE
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TRANSMISSION MODE
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS TYPE
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
    99. 6.99 REST OF MEA MARKET ANALYSIS BY TRANSMISSION MODE
    100. 6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS TYPE
    101. 6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
    102. 6.102 REST OF MEA MARKET ANALYSIS BY END USER
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY TRANSMISSION MODE, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY TRANSMISSION MODE, 2024 TO 2035 (USD Million)
    111. 6.111 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY DIAGNOSIS TYPE, 2024 TO 2035 (USD Million)
    113. 6.113 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
    115. 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.3.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.3.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.3.4 BY END USER, 2025-2035 (USD Million)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.4.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.4.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.4.4 BY END USER, 2025-2035 (USD Million)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.5.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.5.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.5.4 BY END USER, 2025-2035 (USD Million)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.6.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.6.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.6.4 BY END USER, 2025-2035 (USD Million)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.7.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.7.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.7.4 BY END USER, 2025-2035 (USD Million)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.8.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.8.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.8.4 BY END USER, 2025-2035 (USD Million)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.9.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.9.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.9.4 BY END USER, 2025-2035 (USD Million)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.10.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.10.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.10.4 BY END USER, 2025-2035 (USD Million)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.11.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.11.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.11.4 BY END USER, 2025-2035 (USD Million)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.12.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.12.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.12.4 BY END USER, 2025-2035 (USD Million)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.13.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.13.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.13.4 BY END USER, 2025-2035 (USD Million)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.14.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.14.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.14.4 BY END USER, 2025-2035 (USD Million)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.15.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.15.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.15.4 BY END USER, 2025-2035 (USD Million)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.16.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.16.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.16.4 BY END USER, 2025-2035 (USD Million)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.17.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.17.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.17.4 BY END USER, 2025-2035 (USD Million)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.18.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.18.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.18.4 BY END USER, 2025-2035 (USD Million)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.19.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.19.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.19.4 BY END USER, 2025-2035 (USD Million)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.20.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.20.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.20.4 BY END USER, 2025-2035 (USD Million)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.21.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.21.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.21.4 BY END USER, 2025-2035 (USD Million)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.22.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.22.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.22.4 BY END USER, 2025-2035 (USD Million)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.23.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.23.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.23.4 BY END USER, 2025-2035 (USD Million)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.24.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.24.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.24.4 BY END USER, 2025-2035 (USD Million)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.25.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.25.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.25.4 BY END USER, 2025-2035 (USD Million)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.26.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.26.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.26.4 BY END USER, 2025-2035 (USD Million)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.27.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.27.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.27.4 BY END USER, 2025-2035 (USD Million)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.28.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.28.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.28.4 BY END USER, 2025-2035 (USD Million)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.29.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.29.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.29.4 BY END USER, 2025-2035 (USD Million)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY TRANSMISSION MODE, 2025-2035 (USD Million)
      2. 7.30.2 BY DIAGNOSIS TYPE, 2025-2035 (USD Million)
      3. 7.30.3 BY TREATMENT TYPE, 2025-2035 (USD Million)
      4. 7.30.4 BY END USER, 2025-2035 (USD Million)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Hanta Virus Market Segmentation

Hanta Virus Market By Transmission Mode (USD Million, 2025-2035)

  • Inhalation
  • Contact with contaminated surfaces
  • Bite from infected rodents

Hanta Virus Market By Diagnosis Type (USD Million, 2025-2035)

  • Serological Tests
  • Molecular Tests
  • Antigen Tests

Hanta Virus Market By Treatment Type (USD Million, 2025-2035)

  • Supportive Care
  • Antiviral Therapy
  • Vaccination

Hanta Virus Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes